Al Khayyat’s $100m VetHealth bet targets $6.91bn MEA veterinary market

Al Khayyat Investments committed $100 million on 18 June 2026 to launch VetHealth, targeting a $6.91 billion Middle East and Africa veterinary healthcare market by 2033.

For healthcare executives, the takeaway is direct: AKI is using healthcare distribution, diagnostics and regulated supply-chain experience to enter animal health as food security and zoonotic risk draw more government attention.

The $100m platform

VetHealth will operate across five divisions: pharmaceuticals, biologicals, biosecurity, nutrition and diagnostics. According to Al Khayyat Investments, the platform will sell to animal farms, feed mills, veterinary clinics, pharmacies and government entities.

AKI said the MEA veterinary healthcare market is projected to rise to $6.91 billion by 2033, driven by livestock productivity needs and pet ownership. The company said VetHealth will serve commercial animal production and companion animal care from a UAE base.

The size of the commitment gives VetHealth room to act as a distributor, registration partner and operating platform. AKI already has healthcare distribution assets in pharmaceuticals, medical equipment, diagnostics and pharmacy retail, and the group says it employs about 12,000 people across the UAE, GCC, Iraq, Jordan and Egypt.

Why hospital operators should watch

For hospital CEOs and owners, VetHealth is a signal that UAE healthcare groups are testing adjacent sectors where regulation, cold-chain logistics and clinical supply relationships already matter. Animal diagnostics, vaccine handling and biosecurity products require quality systems similar to those used in human healthcare supply chains.

For CFOs, the question is whether animal health becomes a durable margin pool or stays a distribution business with working-capital strain. The $6.91 billion market projection by 2033 gives the opportunity a reference point, but revenue will depend on registrations, supplier terms, inventory depth and government purchasing cycles.

• Commercial animal production: vaccines, feed additives, diagnostics and farm biosecurity.
• Companion animals: clinics, pharmacies, imaging, surgery and preventive products.
• Government buyers: quarantine, food safety, livestock productivity and zoonotic disease control.
• Health-tech suppliers: lab information systems, traceability, tele-triage and inventory control.

Regulatory signal

The UAE animal health market is tied to food security policy. The National Food Security Strategy 2051 sets a national target to rank first in the Global Food Security Index by 2051. Veterinary products, livestock disease control and biosecurity support that policy goal.

The compliance context also changed before the VetHealth launch. The UAE legislation portal lists Federal Decree by Law No. 21 of 2025 on veterinary medical products and veterinary pharmaceutical establishments, with an effective date of 1 January 2026.

The law covers veterinary medicinal products, biologicals, medical devices, warehouses, factories, laboratories, pharmacies, marketing offices and veterinary biobanks. It assigns product registration and marketing authorization controls to the Emirates Drug Establishment, while the Ministry of Climate Change and Environment and emirate-level competent authorities retain defined roles.

For Dubai Health Authority, Department of Health Abu Dhabi and Ministry of Health and Prevention providers, the near-term exposure is indirect. Hospitals will not license VetHealth activity, but medical directors should watch for One Health guidance on infectious disease surveillance, antimicrobial resistance reporting and laboratory standards.

VetHealth now has to turn a $100 million commitment into registrations, supplier partnerships and contracts across more than one jurisdiction. The number to remember is $6.91 billion by 2033; the competitor to watch is AKI as it applies healthcare distribution muscle to animal health.